TAI P HUYNH, DDS
Dentist at 9 Ave, Oakland, CA
License number
California 60599
Category
Dentist
Type
General Practice
Address
Address
1634 9Th Ave, Oakland, CA 94606
Phone
(510) 393-6296
Personal information
See more information about TAI P HUYNH at radaris.comName
Address
Phone
3350 Central Ave, San Diego, CA 92105
3330 Burton Ave, Rosemead, CA 91770
3331 Burton Ave, Rosemead, CA 91770
4239 Queen Anne Dr, Union City, CA 94587
455 E Sunset St, Long Beach, CA 90805
Professional information
Dr. Tai P Huynh, Oakland CA - DDS (Doctor of Dental Surgery)
Specialties:
Dentistry
Address:
1634 9Th Ave, Oakland 94606
Languages:
English
C-Met Modulators And Method Of Use
US Patent:
2012018, Jul 19, 2012
Filed:
Mar 22, 2012
Appl. No.:
13/427093
Inventors:
Lynne Canne Bannen - Lucerne CA, US
Diva Sze-Ming Chan - Oakland CA, US
Jeff Chen - San Francisco CA, US
Lisa Esther Dalrymple - San Francisco CA, US
Timothy Patrick Forsyth - Hayward CA, US
Tai Phat Huynh - Oakland CA, US
Vasu Jammalamadaka - Pleasanton CA, US
Richard George Khoury - San Mateo CA, US
James William Leahy - San Leandro CA, US
Morrison B. Mac - San Francisco CA, US
Grace Mann - Brisbane CA, US
Larry W. Mann - Richland MI, US
John M. Nuss - Danville CA, US
Jason Jevious Parks - Sacramento CA, US
Yong Wang - Foster City CA, US
Wei Xu - Danville CA, US
Diva Sze-Ming Chan - Oakland CA, US
Jeff Chen - San Francisco CA, US
Lisa Esther Dalrymple - San Francisco CA, US
Timothy Patrick Forsyth - Hayward CA, US
Tai Phat Huynh - Oakland CA, US
Vasu Jammalamadaka - Pleasanton CA, US
Richard George Khoury - San Mateo CA, US
James William Leahy - San Leandro CA, US
Morrison B. Mac - San Francisco CA, US
Grace Mann - Brisbane CA, US
Larry W. Mann - Richland MI, US
John M. Nuss - Danville CA, US
Jason Jevious Parks - Sacramento CA, US
Yong Wang - Foster City CA, US
Wei Xu - Danville CA, US
Assignee:
Exelixis, Inc. - South San Francisco CA
International Classification:
A61K 31/4709, A61K 31/517, C07D 215/233, C07D 401/12, A61K 31/47, C07D 239/94, C07D 417/12, C07D 401/10, C07D 413/12, A61K 31/5377, C07D 215/46, C07D 417/14, A61K 31/501, A61K 31/496, A61K 31/513, C12N 9/99, C12Q 1/48, C12Q 1/66, A61P 35/00, A61P 29/00, A61P 37/00, A61P 37/06, A61P 25/00, A61P 17/06, A61P 9/00, A61P 9/10, A61P 1/00, A61P 19/02, A61P 27/02, C07D 403/10
US Classification:
51421018, 544287, 5142662, 546153, 514312, 544293, 5142664, 544128, 5142352, 546160, 514313, 544238, 51425204, 544363, 51425307, 544316, 514274, 51421021, 544119, 5142345, 435184, 435 15, 435 8, 435 71
Abstract:
The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.
Therapeutic Methods Using Electromagnetic Radiation
US Patent:
8343026, Jan 1, 2013
Filed:
May 11, 2012
Appl. No.:
13/469855
Inventors:
Allan Gardiner - Kensington CA, US
Tai Huynh - Oakland CA, US
Tai Huynh - Oakland CA, US
International Classification:
A61N 2/00
US Classification:
600 9
Abstract:
This invention provides methods for treating cold extremities using localized electromagnetic radiation directed at excitable tissues, including nerves, muscles and blood vessels. By controlling the wavelength, the wavelength bandpass, pulse duration, intensity, pulse frequency, and/or variations of those characteristics over time, and by selecting sites of exposure to electromagnetic radiation, improvements in the function of different tissues and organs can be provided. Responses can be monitored by measuring physiological variables including temperature and blood flow.
C-Met Modulators And Method Of Use
US Patent:
2013025, Sep 26, 2013
Filed:
May 7, 2013
Appl. No.:
13/888592
Inventors:
Diva Sze-ming Chan - Oakland CA, US
Jeff Chen - San Francisco CA, US
Timothy Patrick Forsyth - Hayward CA, US
Tai Phat Huynh - Oakland CA, US
Vasu Jammalamadaka - Pleasanton CA, US
Richard George Khoury - San Mateo CA, US
James William Leahy - San Leandro CA, US
Morrison B. Mac - San Francisco CA, US
Larry W. Mann - Richland MI, US
John M. Nuss - Danville CA, US
Jason Jevious Parks - Sacramento CA, US
Craig Stacy Takeuchi - Burlingame CA, US
Yong Wang - Foster City CA, US
Wei Xu - Danville CA, US
Jeff Chen - San Francisco CA, US
Timothy Patrick Forsyth - Hayward CA, US
Tai Phat Huynh - Oakland CA, US
Vasu Jammalamadaka - Pleasanton CA, US
Richard George Khoury - San Mateo CA, US
James William Leahy - San Leandro CA, US
Morrison B. Mac - San Francisco CA, US
Larry W. Mann - Richland MI, US
John M. Nuss - Danville CA, US
Jason Jevious Parks - Sacramento CA, US
Craig Stacy Takeuchi - Burlingame CA, US
Yong Wang - Foster City CA, US
Wei Xu - Danville CA, US
Assignee:
Exelixis, Inc. - South San Francisco CA
International Classification:
C07D 215/233, C07D 413/14, C07D 401/14, C07D 405/14, C07D 295/15, C07D 401/12
US Classification:
51421021, 435 15, 435375, 5142352, 51425505, 51426622, 514307, 514312, 544128, 544287, 544405, 546146, 546153
Abstract:
The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.
C-Met Modulators And Methods Of Use
US Patent:
2007005, Mar 8, 2007
Filed:
Oct 26, 2006
Appl. No.:
11/586751
Inventors:
Lynne Bannen - Pacifica CA, US
Diva Chan - San Francisco CA, US
Jeff Chen - San Francisco CA, US
Lisa Dalrymple - San Francisco CA, US
Timothy Forsyth - Hayward CA, US
Tai Huynh - Oakland CA, US
Vasu Jammalamadaka - Pleasanton CA, US
Richard Khoury - Redwood City CA, US
James Leahy - San Leandro CA, US
Morrison Mac - San Francisco CA, US
Grace Mann - Brisbane CA, US
Larry Mann - Redwood City CA, US
John Nuss - Danville CA, US
Jason Parks - Sacramento CA, US
Craig Takeuchi - Burlingame CA, US
Yong Wang - Foster City CA, US
Wei Xu - Danville CA, US
Diva Chan - San Francisco CA, US
Jeff Chen - San Francisco CA, US
Lisa Dalrymple - San Francisco CA, US
Timothy Forsyth - Hayward CA, US
Tai Huynh - Oakland CA, US
Vasu Jammalamadaka - Pleasanton CA, US
Richard Khoury - Redwood City CA, US
James Leahy - San Leandro CA, US
Morrison Mac - San Francisco CA, US
Grace Mann - Brisbane CA, US
Larry Mann - Redwood City CA, US
John Nuss - Danville CA, US
Jason Parks - Sacramento CA, US
Craig Takeuchi - Burlingame CA, US
Yong Wang - Foster City CA, US
Wei Xu - Danville CA, US
Assignee:
EXELIXIS, INC. - South San Francisco CA
International Classification:
A61K 31/517, A61K 31/4709, C07D 403/02, C07D 401/02
US Classification:
514266200, 514312000, 544284000, 546153000, 514313000, 546159000
Abstract:
The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate and/or modulate kinase receptor, particularly c-Met, KDR, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.
C-Met Modulators And Method Of Use
US Patent:
2007022, Sep 27, 2007
Filed:
May 24, 2007
Appl. No.:
11/753462
Inventors:
Lynne Bannen - Pacifica CA, US
Diva Chan - San Francisco CA, US
Jeff Chen - San Francisco CA, US
Lisa Dalrymple - San Leandro CA, US
Timothy Forsyth - Hayward CA, US
Tai Huynh - Oakland CA, US
Vasu Jammalamadaka - Pleasanton CA, US
Richard Khoury - Redwood City CA, US
James Leahy - San Leandro CA, US
Morrison Mac - San Francisco CA, US
Grace Mann - Brisbane CA, US
Larry Mann - Richland MI, US
John Nuss - Danville CA, US
Jason Parks - Sacramento CA, US
Craig Takeuchi - Burlingame CA, US
Yong Wang - Foster City CA, US
Wie Xu - Danville CA, US
Diva Chan - San Francisco CA, US
Jeff Chen - San Francisco CA, US
Lisa Dalrymple - San Leandro CA, US
Timothy Forsyth - Hayward CA, US
Tai Huynh - Oakland CA, US
Vasu Jammalamadaka - Pleasanton CA, US
Richard Khoury - Redwood City CA, US
James Leahy - San Leandro CA, US
Morrison Mac - San Francisco CA, US
Grace Mann - Brisbane CA, US
Larry Mann - Richland MI, US
John Nuss - Danville CA, US
Jason Parks - Sacramento CA, US
Craig Takeuchi - Burlingame CA, US
Yong Wang - Foster City CA, US
Wie Xu - Danville CA, US
Assignee:
EXELIXIS, INC. - South San Francisco CA
International Classification:
A61K 31/517, A61K 31/4709, A61K 31/4704, C07D 401/02, C07D 403/02, C07D 417/02
US Classification:
514266200, 514312000, 544284000, 546153000
Abstract:
The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.
C-Met Modulators And Method Of Use
US Patent:
8497284, Jul 30, 2013
Filed:
Sep 30, 2011
Appl. No.:
13/249815
Inventors:
Lynne Canne Bannen - Lucerne CA, US
Diva Sze-Ming Chan - Oakland CA, US
Jeff Chen - San Francisco CA, US
Lisa Esther Dalrymple - Seattle WA, US
Timothy Patrick Forsyth - Hayward CA, US
Tai Phat Huynh - Oakland CA, US
Vasu Jammalamadaka - Pleasanton CA, US
Richard George Khoury - San Mateo CA, US
James William Leahy - San Leandro CA, US
Morrison B. Mac - San Francisco CA, US
Grace Mann - San Mateo CA, US
Larry W. Mann - Richland MI, US
John M. Nuss - Danville CA, US
Jason Jevious Parks - Sacramento CA, US
Craig Stacy Takeuchi - Burlingame CA, US
Yong Wang - Foster City CA, US
Wei Xu - Danville CA, US
Diva Sze-Ming Chan - Oakland CA, US
Jeff Chen - San Francisco CA, US
Lisa Esther Dalrymple - Seattle WA, US
Timothy Patrick Forsyth - Hayward CA, US
Tai Phat Huynh - Oakland CA, US
Vasu Jammalamadaka - Pleasanton CA, US
Richard George Khoury - San Mateo CA, US
James William Leahy - San Leandro CA, US
Morrison B. Mac - San Francisco CA, US
Grace Mann - San Mateo CA, US
Larry W. Mann - Richland MI, US
John M. Nuss - Danville CA, US
Jason Jevious Parks - Sacramento CA, US
Craig Stacy Takeuchi - Burlingame CA, US
Yong Wang - Foster City CA, US
Wei Xu - Danville CA, US
Assignee:
Exelixis, Inc. - South San Francisco CA
International Classification:
A61K 31/47
US Classification:
514312, 546153
Abstract:
The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.
Tie-2 Modulators And Methods Of Use
US Patent:
8178570, May 15, 2012
Filed:
Apr 8, 2004
Appl. No.:
10/552424
Inventors:
Jeff Chen - San Francisco CA, US
Lisa Esther Dalrymple - San Francisco CA, US
Sergey Epshteyn - Fremont CA, US
Timothy Patrick Forsyth - Hayward CA, US
Tai Phat Huynh - Oakland CA, US
James William Leahy - San Leandro CA, US
Brian Hugh Ridgway - Belmont CA, US
Grace Mann - Brisbane CA, US
Larry W. Mann - Richland MI, US
Craig Stacy Takeuchi - Burlingame CA, US
Joan C. Sangalang - Mountain View CA, US
Lisa Esther Dalrymple - San Francisco CA, US
Sergey Epshteyn - Fremont CA, US
Timothy Patrick Forsyth - Hayward CA, US
Tai Phat Huynh - Oakland CA, US
James William Leahy - San Leandro CA, US
Brian Hugh Ridgway - Belmont CA, US
Grace Mann - Brisbane CA, US
Larry W. Mann - Richland MI, US
Craig Stacy Takeuchi - Burlingame CA, US
Joan C. Sangalang - Mountain View CA, US
Assignee:
Exelixis, Inc. - South San Francisco CA
International Classification:
A01N 43/64, A01N 43/54, A61K 31/41, C07D 239/42, C07D 401/04, C07D 249/08
US Classification:
514383, 514256, 5482622
Abstract:
The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly Tie-2. Methods of using the compounds and pharmaceutical compositions thereof to treat kinase-dependent diseases and conditions are also an aspect of the invention.
C-Met Modulators And Methods Of Use
US Patent:
8067436, Nov 29, 2011
Filed:
May 24, 2007
Appl. No.:
11/753514
Inventors:
Lynne Canne Bannen - Pacifica CA, US
Diva Sze-Ming Chan - San Francisco CA, US
Jeff Chen - San Francisco CA, US
Lisa Esther Dalrymple - San Leandro CA, US
Timothy Patrick Forsyth - Hayward CA, US
Tai Phat Huynh - Oakland CA, US
Vasu Jammalamadaka - Pleasanton CA, US
Richard George Khoury - Redwood City CA, US
James William Leahy - San Leandro CA, US
Morrisson B. Mac - San Francisco CA, US
Grace Mann - Brisbane CA, US
Larry W. Mann - Richland MI, US
John M. Nuss - Danville CA, US
Jason Jevious Parks - Sacramento CA, US
Craig Stacy Takeuchi - Burlingame CA, US
Yong Wang - Forster City CA, US
Wie Xu - Danville CA, US
Diva Sze-Ming Chan - San Francisco CA, US
Jeff Chen - San Francisco CA, US
Lisa Esther Dalrymple - San Leandro CA, US
Timothy Patrick Forsyth - Hayward CA, US
Tai Phat Huynh - Oakland CA, US
Vasu Jammalamadaka - Pleasanton CA, US
Richard George Khoury - Redwood City CA, US
James William Leahy - San Leandro CA, US
Morrisson B. Mac - San Francisco CA, US
Grace Mann - Brisbane CA, US
Larry W. Mann - Richland MI, US
John M. Nuss - Danville CA, US
Jason Jevious Parks - Sacramento CA, US
Craig Stacy Takeuchi - Burlingame CA, US
Yong Wang - Forster City CA, US
Wie Xu - Danville CA, US
Assignee:
Exelixis, Inc. - South San Francisco CA
International Classification:
A61K 31/47, A61K 31/4709, A61K 31/517, A61K 31/5377
US Classification:
514312, 546153, 544119, 544287, 544363, 544128, 5142345, 5142352, 51425217, 51425307, 5142662, 51426622, 5142663
Abstract:
The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.
Protein Kinase Modulators And Methods Of Use
US Patent:
2006021, Sep 21, 2006
Filed:
May 2, 2003
Appl. No.:
10/513081
Inventors:
Chris Buhr - Redwood City CA, US
Sunghoon Ma - Foster City CA, US
Zerom Tesfai - San Leandro CA, US
Longcheng Wang - South San Francisco CA, US
Erick Co - Redwood City CA, US
Sergey Epshteyn - Fremont CA, US
Abigail Kennedy - San Leandro CA, US
Baili Chen - Palo Alto CA, US
Larisa Dubenko - San Francisco CA, US
Neel Anand - Burlingame CA, US
Tsze Tsang - El Cerrito CA, US
John Nuss - Danville CA, US
Kenneth Rice - Mill Valley CA, US
Mohamed Ibrahim - Mountain View CA, US
Xian Shi - San Bruno CA, US
James Leahy - San Leandro CA, US
Jeff Chen - San Francisco CA, US
Lisa Dalrymple - San Francisco CA, US
Timothy Forsyth - Hayward CA, US
Tai Huynh - Oakland CA, US
Grace Mann - Brisbane CA, US
Larry Mann - Redwood City CA, US
Craig Takeuchi - Burlingame CA, US
Sunghoon Ma - Foster City CA, US
Zerom Tesfai - San Leandro CA, US
Longcheng Wang - South San Francisco CA, US
Erick Co - Redwood City CA, US
Sergey Epshteyn - Fremont CA, US
Abigail Kennedy - San Leandro CA, US
Baili Chen - Palo Alto CA, US
Larisa Dubenko - San Francisco CA, US
Neel Anand - Burlingame CA, US
Tsze Tsang - El Cerrito CA, US
John Nuss - Danville CA, US
Kenneth Rice - Mill Valley CA, US
Mohamed Ibrahim - Mountain View CA, US
Xian Shi - San Bruno CA, US
James Leahy - San Leandro CA, US
Jeff Chen - San Francisco CA, US
Lisa Dalrymple - San Francisco CA, US
Timothy Forsyth - Hayward CA, US
Tai Huynh - Oakland CA, US
Grace Mann - Brisbane CA, US
Larry Mann - Redwood City CA, US
Craig Takeuchi - Burlingame CA, US
International Classification:
A61K 31/497, C07D 403/02
US Classification:
514255050, 544405000
Abstract:
Substituted aryl 1,4-pyrazine derivatives and their use in treating anxiety disorders, depression and stress related disorders are disclosed.